Research Topics
| C SchiepersSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathwayJohannes Schwarzenberg
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Division, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
Eur J Nucl Med Mol Imaging 38:711-21. 2011..Here we present the biodistribution and radiation dosimetry of three fluorinated dCK substrates, (18)F-FAC, L: -(18)F-FAC, and L: -(18)F-FMAC, developed for positron emission tomography (PET) imaging of dCK activity in vivo...- Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imagingChristiaan Schiepers
Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, 200 Medical Plaza, Suite B 114, Los Angeles, CA, 90095 7370, USA
Eur Radiol 21:548-54. 2011..The combination of these imaging modalities is challenging, but has particular features such as imaging biological processes at the same time in specific body locations... - 18F-fluorothymidine kinetics of malignant brain tumorsChristiaan Schiepers
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, AR 144 CHS 10833 Le Conte Avenue, Los Angeles, CA 90095 6942, USA
Eur J Nucl Med Mol Imaging 34:1003-11. 2007..18F-labeled deoxy-fluorothymidine (FLT), a marker of cellular proliferation, has been used in PET tumor imaging. Here, the FLT kinetics of malignant brain tumors were investigated... - 18F-FDOPA kinetics in brain tumorsChristiaan Schiepers
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA
J Nucl Med 48:1651-61. 2007..Evaluation of tumor recurrence in neurooncology is another application. Here, the kinetics of (18)F-FDOPA in brain tumors were investigated... - PET for staging of Hodgkin's disease and non-Hodgkin's lymphomaChristiaan Schiepers
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, CA 90095 6948, Los Angeles, USA
Eur J Nucl Med Mol Imaging 30:S82-8. 2003..Highly variable results have been reported on whether up- or downstaging of lymphoma with PET leads to changes in the therapeutic approach for primary lymphoma... - 1-11C-acetate kinetics of prostate cancerChristiaan Schiepers
Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California 90095 6942, USA
J Nucl Med 49:206-15. 2008..1-(11)C-Labeled acetate, a substrate for the citric acid cycle, is superior. The kinetics of prostate tumors were investigated... - Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade gliomaChristiaan Schiepers
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California 90095 6942, USA
J Nucl Med 51:720-7. 2010..3'-Deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) is used as a biomarker of cell proliferation. We investigated the kinetics of (18)F-FLT during treatment of malignant glioma with bevacizumab and irinotecan... - Surgical correction of vesicoureteral reflux: 5-year follow-up with 99Tcm-DMSA scintigraphyC Schiepers
Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, CA 90095, USA
Nucl Med Commun 22:217-24. 2001..To evaluate kidney function before and after surgical correction of vesicoureteral reflux. The long-term effect was measured with quantitative nephro-scintigraphy using 99Tcm labelled dimercaptosuccinic acid (99Tcm-DMSA)... - Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspectiveJ Meta
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic, and Nuclear Medicine, University of California, Los Angeles, School of Medicine, Los Angeles, CA, USA
J Nucl Med 42:586-90. 2001.... - Decision analysis for the cost-effective management of recurrent colorectal cancerK C Park
Crump Institute for Molecular Imaging, the Department of Molecular and Medical Pharmacology, the Division of Nuclear Medicine, UCLA School of Medicine, Los Angeles, California 90095, USA
Ann Surg 233:310-9. 2001..The decision trees can be used to model various features of the management of recurrent CRC, including the cost-effectiveness of other newly emerging technologies... - 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracyWei Chen
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
J Nucl Med 47:904-11. 2006..18)F-FDOPA PET may prove especially useful for imaging of recurrent low-grade tumors and for distinguishing tumor recurrence from radiation necrosis... - Measurement of skeletal flow with positron emission tomography and 18F-fluoride in femoral head osteonecrosisC Schiepers
Olive View UCLA Medical Center 91342, USA
Arch Orthop Trauma Surg 118:131-5. 1998..Our preliminary study indicates that this type of highly technical investigation appears feasible in clinical practice and permits prediction of the outcome depending upon regional skeletal flow measurements in vivo... - Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT studyBenjamin S Halpern
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, California 90095-6942, USA
J Nucl Med 46:603-7. 2005..Thus, 5 min/bed position scans are sufficient for optimal lesion detection with LSO PET/CT in obese patients... - Evaluation of metastatic meningioma with 2-deoxy-2-[18F]fluoro-D-glucose PET/CTMaziar Ghodsian
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
Clin Nucl Med 30:717-20. 2005..CONCLUSIONS: Although meningioma is typically a benign tumor, in rare instances, it metastasizes. The current case example exhibits moderately increased metabolism despite findings of high-grade malignancy on biopsy... - Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomographyCecelia S Yap
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center/Nuclear Medicine, UCLA School of Medicine, AR-144 CHS, Los Angeles, CA 90095-6948, USA
Chest 129:393-401. 2006..Nevertheless, the correlation between FLT uptake and cellular proliferation suggests that future studies should evaluate the use of FLT-PET for monitoring treatment with cytostatic anticancer drugs... - Cardiac pacemakers and central venous lines can induce focal artifacts on CT-corrected PET imagesBenjamin S Halpern
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic/Nuclear Medicine, UCLA School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
J Nucl Med 45:290-3. 2004..Thus, in patients with permanent central lines or pacemakers, both corrected and uncorrected PET images need to be reviewed to avoid false-positive PET findings... - Accuracy of PET/CT in characterization of solitary pulmonary lesionsShanna K Kim
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California 90095 6942, USA
J Nucl Med 48:214-20. 2007..The performance of dual-modality imaging with PET/CT for characterizing SPNs was investigated in a clinical referral setting... - PET/CT in Colorectal CancerChristiaan Schiepers
David Geffen School of Medicine at UCLA, Los Angeles, California 90095-6948, USA
J Nucl Med 44:1804-5. 2003 - Molecular mechanisms of bone 18F-NaF depositionJohannes Czernin
Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095 1782, USA
J Nucl Med 51:1826-9. 2010.... - Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomasBarbara J Fueger
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
J Nucl Med 51:1532-8. 2010..The aims of the current study were to determine whether the degree of (18)F-FDOPA uptake in brain tumors predicted tumor grade and was associated with tumor proliferative activity in newly diagnosed and recurrent gliomas... - The impact of PET on the management of lung cancer: the referring physician's perspectiveMarc A Seltzer
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic/Nuclear Medicine, UCLA School of Medicine, Los Angeles, California 90095-6948, USA
J Nucl Med 43:752-6. 2002..CONCLUSION: This survey-based study of referring physicians suggests that PET has a major impact on staging and management of lung cancer... - FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma?Cecelia S Yap
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center/Nuclear Medicine, UCLA School of Medicine, AR-259 CHS, Los Angeles, CA 90095-6948, USA
Eur J Nucl Med Mol Imaging 29:1166-73. 2002..PET is less accurate in patients with rare BAC tumors that have no invasive component... - Relationship between 18F-FDG uptake and breast density in women with normal breast tissueDuska Vranjesevic
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic/Nuclear Medicine, UCLA School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095-6942, USA
J Nucl Med 44:1238-42. 2003..5 commonly used as a cutoff between benign and malignant tissue. Therefore, breast density is unlikely to affect the ability of (18)F-FDG PET to discriminate between benign and malignant breast lesions... - Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspectiveC S Yap
Ahmanson Biological Imaging Center/Nuclear Medicine Clinic, Department of Molecular and Medical Pharmacology, UCLA School of Medicine, University of California, Los Angeles, USA
J Nucl Med 42:1334-7. 2001..CONCLUSION: The results of this prospective survey show that FDG PET has a major impact on the management of breast cancer patients, influencing both clinical stage and management in more than 30% of patients... - Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusionBenjamin S Halpern
Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, AR 128 CHS, 10833 Le Conte Ave, Los Angeles, CA 90095-6942, USA
Chest 128:2289-97. 2005..CONCLUSIONS: Integrated PET/CT compared with PET alone was associated with 26% points-greater overall diagnostic accuracy (p = 0.01). The software fusion method failed to provide acceptable co-registration in > 30% of the patients...